HighTower Advisors
RPRX icon

HighTower Advisors’s Royalty Pharma RPRX Stock Holding History

HighTower Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,000
Closed -$1.12K – 3945
2023
Q4 		$1.12K Buy
5,000
+4,990
+49,900% +$137K ﹤0.01% 3535
2023
Q3 		$2 Sell
10
-110
-92% -$3.27K ﹤0.01% 3557
2023
Q2 		$7.4K Buy
+120
New +$4.06K ﹤0.01% 3321

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

HighTower Advisors's RPRX Position: Q3 2026 in Review

HighTower Advisors reduced its Royalty Pharma (RPRX) stake by 1.2% in Q3 2026, selling an estimated $201K and leaving 282,231 shares worth $16.5M. The position accounts for 0.02% of the portfolio, ranked #723.

HighTower Advisors first reported a position in RPRX in Q2 2021 and has held it in 22 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • HighTower Advisors held 282,231 shares of Royalty Pharma worth $16.5M as of Q3 2026.
  • HighTower Advisors sold 3,399 Royalty Pharma shares in Q3 2026, an estimated $201K.
  • Royalty Pharma made up 0.02% of HighTower Advisors's portfolio in Q3 2026, its #723 holding.
  • HighTower Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 22 quarters since.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.